Relmada Therapeutics Inc (RLMD)
3.89
+0.21
(+5.71%)
USD |
NASDAQ |
May 06, 16:00
3.89
0.00 (0.00%)
After-Hours: 18:25
Relmada Therapeutics Net Income (Quarterly): -25.17M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -25.17M |
| September 30, 2023 | -22.00M |
| June 30, 2023 | -25.30M |
| March 31, 2023 | -26.32M |
| December 31, 2022 | -37.94M |
| September 30, 2022 | -39.42M |
| June 30, 2022 | -39.94M |
| March 31, 2022 | -39.75M |
| December 31, 2021 | -34.38M |
| September 30, 2021 | -42.61M |
| June 30, 2021 | -26.55M |
| March 31, 2021 | -22.22M |
| December 31, 2020 | -20.76M |
| September 30, 2020 | -16.90M |
| June 30, 2020 | -11.12M |
| March 31, 2020 | -10.67M |
| September 30, 2019 | -3.670M |
| June 30, 2019 | -4.123M |
| March 31, 2019 | -2.686M |
| December 31, 2018 | -7.129M |
| September 30, 2018 | -3.380M |
| June 30, 2018 | -3.350M |
| March 31, 2018 | -3.202M |
| Date | Value |
|---|---|
| December 31, 2017 | -1.427M |
| September 30, 2017 | -0.9817M |
| June 30, 2017 | -1.634M |
| March 31, 2017 | -1.982M |
| December 31, 2016 | -1.031M |
| September 30, 2016 | -1.641M |
| June 30, 2016 | -3.317M |
| March 31, 2016 | -1.860M |
| December 31, 2015 | -2.461M |
| September 30, 2015 | 4.663M |
| June 30, 2015 | 6.042M |
| March 31, 2015 | -2.463M |
| December 31, 2014 | 5.455M |
| September 30, 2014 | -29.84M |
| February 28, 2014 | -0.0031M |
| November 30, 2013 | -0.0144M |
| August 31, 2013 | -0.0124M |
| May 31, 2013 | -0.0195M |
| February 28, 2013 | -0.0041M |
| November 30, 2012 | -0.009M |
| August 31, 2012 | -0.0086M |
| May 31, 2012 | -0.0025M |
| February 29, 2012 | -0.0005M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-42.61M
Minimum
Sep 2021
-3.670M
Maximum
Sep 2019
-24.94M
Average
-25.23M
Median
Net Income (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | -5.271M |
| Lifecore Biomedical Inc | -36.13M |
| Harrow Inc | -9.148M |
| Corvus Pharmaceuticals Inc | -6.653M |
| Aquestive Therapeutics Inc | -8.111M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 26.83M |
| EPS Diluted (Quarterly) | -0.83 |
| Enterprise Value | 14.72M |
| Earnings Yield | -84.06% |
| Normalized Earnings Yield | -0.8902 |